Coral Gables, FL - Stiefel Laboratories, Inc., the world’’s largest independent pharmaceutical company specializing in dermatology, announced today that it has completed its previously announced acquisition of Princeton, New Jersey-based Barrier Therapeutics, Inc. Upon the closing of the acquisition, all remaining outstanding shares of Barrier common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law, were converted into the right to receive $4.15 per share in cash. Effective with the close of trading on August 6, 2008, shares of Barrier will no longer be listed on the NASDAQ Global Market. (more…)
CHARLOTTESVILLE, VA and NEWTON, Mass. — Clinical Data, Inc. (NASDAQ:CLDA) today announced the acquisition of Adenosine Therapeutics, L.L.C., a developer of drug products based on its extensive portfolio of composition of matter and method of use patents relating to selective adenosine receptor modulators. In exchange for all of the company’s operating assets, Clinical Data paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate $3.2 million, 32-month promissory note. Contingent consideration of up to $30 million in cash may be paid on achievement of certain regulatory and commercial milestones. (more…)
Norcross, GA.-Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has closed its previously- announced acquisition of BioArray Solutions Ltd. (more…)
Sunrise, FL -Bioheart Inc. (Nasdaq:BHRT) has entered a non-binding letter of intent to buy Poland’s Medicalalgorithmics and worldwide rights to its Pocketecg.
(more…)
Buford, Ga–Theragenics Corporation(R) (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it completed the acquisition of NeedleTech Products, Inc., on July 28, 2008. The agreement to acquire NeedleTech for $47.8 million was previously announced by Theragenics on July 16, 2008. (more…)
WEST PALM BEACH, FL — The Palm Beach County Commission today approved a plan to give the Max Planck Society of Germany almost $87 million to set up an institute near Scripps Florida in Jupiter. (more…)
Alpharetta, GA - Alimera Sciences, a biopharmaceutical company developing prescription opthalmic products, has filed with the U.S. Securities and Exchange Commission to raise about $75 million in an initial public offering of stock. (more…)
Atlanta, GA–Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals, Inc. to develop and market ADX415, a novel patented, centrally-acting alpha adrenergic receptor agonist, specific to Alpha-2 receptors, for the treatment of hypertension and other potential indications. Under the terms of the agreement, Sciele will have the worldwide marketing rights for ADX415, will pay the product development costs, and will also make regulatory milestone payments and royalty payments to Addrenex on product sales. Sciele and Addrenex expect to begin the Phase II clinical studies in the second half of 2008. (more…)
ALACHUA, FL - Oragenics Inc. (ONI BioPharma Inc.) (AMEX: ONI) has entered into a definitive financing agreement providing for equity financing of $2,600,000 consisting of common stock at 45 cents per share and warrants with an exercise price of $1.30 per share. (more…)
MANCHESTER, UK – Myconostica, a Manchester UK-based medical diagnostic company which specialises in rapid and highly specific tests for life-threatening fungal infections, has completed the third close of a $10.8 million round of financing with a $2 million investment from the UMIP Premier Fund. The company is building a South Carolina facility. (more…)
